Case report: Emerging therapies for transformed small cell lung cancer: efficacy of serplulimab and a comprehensive case report
This research reports a case of histological transformation from non-small cell lung cancer (NSCLC) to transformed small cell lung cancer (T-SCLC) in a patient undergoing EGFR-tyrosine kinase inhibitors (TKIs). The aggressive characteristics of the tumor diverged significantly from those commonly as...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-09-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1406515/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850264401308811264 |
|---|---|
| author | Heng-Xu Lyu Wen-Hua Ma Yong-Qian Zhang Hui Jin Yu-Dong Wang Min Zhao |
| author_facet | Heng-Xu Lyu Wen-Hua Ma Yong-Qian Zhang Hui Jin Yu-Dong Wang Min Zhao |
| author_sort | Heng-Xu Lyu |
| collection | DOAJ |
| description | This research reports a case of histological transformation from non-small cell lung cancer (NSCLC) to transformed small cell lung cancer (T-SCLC) in a patient undergoing EGFR-tyrosine kinase inhibitors (TKIs). The aggressive characteristics of the tumor diverged significantly from those commonly associated with lung adenocarcinomas, leading to further histological analysis. The subsequent histological examination confirmed the transformation to SCLC, consistent with established mechanisms of acquired resistance in NSCLC. Given the limited therapeutic options, the patient was administered a serplulimab-based immunochemotherapy regimen, achieving a progression-free survival (PFS) of 6 months post-transformation. The study underscores the potential of PD-1 inhibitors, particularly serplulimab, in the treatment landscape for T-SCLC and highlights the need for future comprehensive research. |
| format | Article |
| id | doaj-art-f3389cde37e045c8b66285ae02b24159 |
| institution | OA Journals |
| issn | 2296-858X |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-f3389cde37e045c8b66285ae02b241592025-08-20T01:54:42ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2024-09-011110.3389/fmed.2024.14065151406515Case report: Emerging therapies for transformed small cell lung cancer: efficacy of serplulimab and a comprehensive case reportHeng-Xu Lyu0Wen-Hua Ma1Yong-Qian Zhang2Hui Jin3Yu-Dong Wang4Min Zhao5Department of Oncology, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaDepartment of Oncology, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaDepartment of Oncology, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaDepartment of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, ChinaDepartment of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, ChinaDepartment of Oncology, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaThis research reports a case of histological transformation from non-small cell lung cancer (NSCLC) to transformed small cell lung cancer (T-SCLC) in a patient undergoing EGFR-tyrosine kinase inhibitors (TKIs). The aggressive characteristics of the tumor diverged significantly from those commonly associated with lung adenocarcinomas, leading to further histological analysis. The subsequent histological examination confirmed the transformation to SCLC, consistent with established mechanisms of acquired resistance in NSCLC. Given the limited therapeutic options, the patient was administered a serplulimab-based immunochemotherapy regimen, achieving a progression-free survival (PFS) of 6 months post-transformation. The study underscores the potential of PD-1 inhibitors, particularly serplulimab, in the treatment landscape for T-SCLC and highlights the need for future comprehensive research.https://www.frontiersin.org/articles/10.3389/fmed.2024.1406515/fulltransformed small cell lung cancer (T-SCLC)immune checkpoint inhibitors (ICIs)immunotherapynon-small cell lung cancer (NSCLC)case report |
| spellingShingle | Heng-Xu Lyu Wen-Hua Ma Yong-Qian Zhang Hui Jin Yu-Dong Wang Min Zhao Case report: Emerging therapies for transformed small cell lung cancer: efficacy of serplulimab and a comprehensive case report Frontiers in Medicine transformed small cell lung cancer (T-SCLC) immune checkpoint inhibitors (ICIs) immunotherapy non-small cell lung cancer (NSCLC) case report |
| title | Case report: Emerging therapies for transformed small cell lung cancer: efficacy of serplulimab and a comprehensive case report |
| title_full | Case report: Emerging therapies for transformed small cell lung cancer: efficacy of serplulimab and a comprehensive case report |
| title_fullStr | Case report: Emerging therapies for transformed small cell lung cancer: efficacy of serplulimab and a comprehensive case report |
| title_full_unstemmed | Case report: Emerging therapies for transformed small cell lung cancer: efficacy of serplulimab and a comprehensive case report |
| title_short | Case report: Emerging therapies for transformed small cell lung cancer: efficacy of serplulimab and a comprehensive case report |
| title_sort | case report emerging therapies for transformed small cell lung cancer efficacy of serplulimab and a comprehensive case report |
| topic | transformed small cell lung cancer (T-SCLC) immune checkpoint inhibitors (ICIs) immunotherapy non-small cell lung cancer (NSCLC) case report |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1406515/full |
| work_keys_str_mv | AT hengxulyu casereportemergingtherapiesfortransformedsmallcelllungcancerefficacyofserplulimabandacomprehensivecasereport AT wenhuama casereportemergingtherapiesfortransformedsmallcelllungcancerefficacyofserplulimabandacomprehensivecasereport AT yongqianzhang casereportemergingtherapiesfortransformedsmallcelllungcancerefficacyofserplulimabandacomprehensivecasereport AT huijin casereportemergingtherapiesfortransformedsmallcelllungcancerefficacyofserplulimabandacomprehensivecasereport AT yudongwang casereportemergingtherapiesfortransformedsmallcelllungcancerefficacyofserplulimabandacomprehensivecasereport AT minzhao casereportemergingtherapiesfortransformedsmallcelllungcancerefficacyofserplulimabandacomprehensivecasereport |